Congress Materials – International Prostate Cancer Update (IPCU 2025)
2025 International Prostate Cancer Update | Feb 9-12 | Vail, CO
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Descriptive Analysis of Treatment Patterns and Clinical Outcomes in Patients with Metastatic Castration Sensitive Prostate Cancer (mCSPC) who initiated Apalutamide or Darolutamide in U.S. Community Urology Practices
Sabree Burbage, Cindy Chen, Lorie Ellis, Ruibin Wang
Comparison of real-world overall survival in subgroups of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide
Mehmet A. Bilen, Benjamin Lowentritt, Sabree Burbage, Kruti Joshi, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Gordon Wong, Dominic Pilon, Lorie Ellis, Neal Shore
Head-to-head comparison of overall survival in subgroups of patients with metastatic castration-sensitive prostate cancer initiating apalutamide or abiraterone acetate - A real-world study
Benjamin Lowentritt, Mehmet A. Bilen, Sabree Burbage, Kruti Joshi, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Gordon Wong, Dominic Pilon, Lorie Ellis, Neal Shore
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.